182 related articles for article (PubMed ID: 28677013)
1. A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer.
Huang J; Gu T; Ying J
Int J Clin Oncol; 2017 Dec; 22(6):1015-1025. PubMed ID: 28677013
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
4. Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: A meta-analysis.
Liu B; Zhao Y; Yuan J; Zeng L; Sun R; Meng X; Yang S
PLoS One; 2017; 12(11):e0187860. PubMed ID: 29182642
[TBL] [Abstract][Full Text] [Related]
5. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of bone metabolic markers in breast cancer with bone metastasis.
Wada N; Fujisaki M; Ishii S; Ikeda T; Kitajima M
Breast Cancer; 2001; 8(2):131-7. PubMed ID: 11342986
[TBL] [Abstract][Full Text] [Related]
7. [Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases].
Xin Y; Han B; Lou J; Wu J; Niu Y
Zhongguo Fei Ai Za Zhi; 2010 Oct; 13(10):947-53. PubMed ID: 20959067
[TBL] [Abstract][Full Text] [Related]
8. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer.
Horiguchi T; Tachikawa S; Kondo R; Hirose M; Teruya S; Ishibashi A; Banno K
Jpn J Clin Oncol; 2000 Apr; 30(4):174-9. PubMed ID: 10830985
[TBL] [Abstract][Full Text] [Related]
10. Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors.
Zhao H; Han KL; Wang ZY; Chen Y; Li HT; Zeng JL; Shen Z; Yao Y
Med Sci Monit; 2011 Nov; 17(11):CR626-633. PubMed ID: 22037741
[TBL] [Abstract][Full Text] [Related]
11. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
12. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.
Tamada T; Sone T; Tomomitsu T; Jo Y; Tanaka H; Fukunaga M
J Bone Miner Metab; 2001; 19(1):45-51. PubMed ID: 11156473
[TBL] [Abstract][Full Text] [Related]
13. The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer.
Bayrak SB; Ceylan E; Serter M; Karadağ F; Demir E; Çildağ O
Int J Clin Oncol; 2012 Apr; 17(2):112-8. PubMed ID: 21691728
[TBL] [Abstract][Full Text] [Related]
14. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
Alcaraz A; González-López R; Morote J; de la Piedra C; Meseguer C; Esteban E; Climent M; González-Gragera B; Alvarez-Ossorio JL; Chirivella I; Mellado B; Lara PC; Vázquez F; Contreras JA; Carles J; Murias A; Calderero V; Comet-Batlle J; González-Del Alba A; León-Mateos L; Mañas A; Segarra J; Lassa A; González-Enguita C; Méndez MJ; Samper P; Unda M; Mahillo-Fernández I; Bellmunt J;
Br J Cancer; 2013 Jul; 109(1):121-30. PubMed ID: 23799855
[TBL] [Abstract][Full Text] [Related]
15. Bone turnover markers and novel biomarkers in lung cancer bone metastases.
Lang J; Zhao Q; He Y; Yu X
Biomarkers; 2018 Sep; 23(6):518-526. PubMed ID: 29683727
[TBL] [Abstract][Full Text] [Related]
16. [Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases].
Koizumi M; Yamada Y; Takiguchi T; Suzuki C; Akashi T; Nomura E; Yamashita T; Ogata E
Kaku Igaku; 1996 Jan; 33(1):77-84. PubMed ID: 8819718
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
18. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
19. Bone remodeling markers in the detection of bone metastases in prostate cancer.
de la Piedra C; Castro-Errecaborde NA; Traba ML; Méndez-Dávila C; García-Moreno C; Rodriguez de Acuña L; Rodriguez-Molina J
Clin Chim Acta; 2003 May; 331(1-2):45-53. PubMed ID: 12691863
[TBL] [Abstract][Full Text] [Related]
20. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
